Vancouver, British Columbia - BioMark Diagnostics Inc. (“BioMark”) (BUX:CNX) (FSE: 20B) (BMKDF) is pleased to announce that it has partnered with The Metabolomics Innovation Centre (“TMIC”), a Genome Canada-funded Science and Technology Innovation Centre located at the University of Alberta and University of Victoria. TMIC provides scientific expertise, analytical services, bioinformatics tools, and customized technology development which complements BioMark’s future research directions in lung, prostate, breast and colon cancer. This relationship will strengthen BioMark’s capabilities and resources in the discovery, validation and translation of future metabolomic-based diagnostic tests for early cancer detection. In collaboration with TMIC, BioMark plans to develop additional novel tests for point-of-care testing.
Dr. David Wishart, Professor at the University of Alberta and Director of TMIC states: “TMIC is very excited about collaborating with BioMark to develop and identify new metabolite biomarkers in early lung cancer detection and potentially for assessing response to treatment. TMIC looks forward to a very productive collaboration with BioMark. “
Both TMIC and BioMark will be presenting an abstract at the 11th International Conference of The Metabolomics Society to be held between June 29th to July 2nd at the University of California, Davis USA.
President and CEO of BioMark, Rashid Ahmed says: “We are delighted to be collaborating with TMIC which is Canada’s leading centre for advancement in metabolomics. This is a strategic partnership for BioMark since our technology is metabolomics based.”
The Metabolomics Innovation Centre (TMIC) is a Genome Canada funded Science & Technology Innovation Centre for metabolomics research, technology development and services. TMIC builds on metabolomics expertise at the University of Alberta and the University of Victoria, which includes $20 million in state-of-the-art metabolomics equipment and ongoing investment for “omics” research and technologies by Genome Canada, Genome British Columbia and Genome Alberta. TMIC’s technologies are based on NMR, mass spectrometry, gas chromatography and novel bioinformatics tools to support clinical trial research, biomedical studies, agricultural studies, nutrient profiling and environmental testing for applications such as human health and disease, petroleum research, forensics, food and nutrition, anti-doping, and textile sciences. TMIC provides access to cutting-edge metabolomic and bioinformatics technologies for Genome Canada-funded projects and the broader research community including government, academia and industry. For more information, visit www.metabolomicscentre.ca.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.
The CSE has not reviewed, approved or disapproved the content of this press release.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer